N4 Pharma Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also engages in the development of N4 101, an orally delivered inflammation inhibitor which is in the pre-clinical development for treatment of inflammatory bowel disease; and ECP105 for the prevention of ocular scarring. N4 Pharma Plc was incorporated in 1979 and is based in London, the United Kingdom.
Metrics to compare | N4P | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipN4PPeersSector | |
---|---|---|---|---|
P/E Ratio | −4.5x | −3.9x | −0.7x | |
PEG Ratio | −0.11 | −0.10 | 0.00 | |
Price/Book | 2.8x | 2.3x | 2.6x | |
Price / LTM Sales | 706.7x | 2.4x | 3.4x | |
Upside (Analyst Target) | - | 78.7% | 37.9% | |
Fair Value Upside | Unlock | 6.7% | 5.2% | Unlock |